DATA AND SAFETY MONITORING

数据和安全监控

• 批准号: 7414810
• 负责人: PETER D. EMANUEL
• 金额: $ 9.15万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-05-01 至 2010-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7414810
• 关键词: Adherence; Adverse event; Clinical Investigator; Clinical Research; Comprehensive Cancer Center; Data; Data Quality; Grant; Human Resources; Monitor; Monitoring Clinical Trials; Nursing Research; Pharmacy facility; Policies; Procedures; Process; Protocols documentation; Reporting; Research Ethics Committees; Review Committee; Safety; Time; United States Food and Drug Administration; human subject; improved; quality assurance

DESCRIPTION (provided by applicant): Since the last submission of this grant, the requirements for assurance of adherence to protocol-specific procedures and rules of human subjects' protection have increased. The requirements have been the result of national (FDA, OHRP, NCI) and local IRB policies. The NCI now requires that each Comprehensive Cancer Center develop an approved DSMP. We have significantly enhanced our monitoring and oversight activities and this has resulted in improved data quality and protocol adherence. However, these improvements have resulted in significant increases in personnel commitments and expense. The process we use for safety and protocol progress review is rigorous using a Clinical Trial Monitoring Review Committee meeting which meets weekly and reviews all active protocols for accrual, adverse events, and problems in "real time". The meetings are chaired by the Associate Director for Clinical Research and involve multiple clinical investigators, research nurses, data managers, pharmacy and regulatory staff. Weekly reports of safety/adverse events are referred to our Quality Assurance Committee (QAC) Director (Dr Carla Falkson) for review. Routine and "for cause" audits are coordinated by the QAC with reports to the Center Director, IRB and regulatory agencies as appropriate.

描述（由申请人提供）：自本赠款的最后一次提交以来，保证遵守特定于协议的程序和人类受试者保护规则的要求有所增加。 这些要求是国家（FDA，OHRP，NCI）和当地IRB政策的结果。 NCI现在要求每个综合癌症中心都开发经批准的DSMP。 我们大大提高了我们的监视和监督活动，这导致了数据质量和协议依从性的提高。 但是，这些改进导致人员承诺和费用大大增加。 我们用于安全和协议进度审查的过程使用临床试验监测审查委员会会议进行了严格的审查，该委员会会议符合每周，并在“实时”中审查所有主动协议，以实现应计，不良事件和问题。 会议由临床研究副主任主持，涉及多个临床研究人员，研究护士，数据经理，药房和监管人员。 每周有关安全/不利事件的报告，请转介我们的质量保证委员会（QAC）主任（Carla Falkson博士）进行审查。 QAC与日常审核和“原因”审核与报告的报告 IRB和监管机构中心主任。